A Study of VG712 in Patients With Mycosis Fungoides
Plain-language summary
This Phase 2 trial is comparing VG712 and Mogamulizumab against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 1 US location.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
VG712 (DRUG): Recombinant anti-CD3 immunotoxin fusion protein composed of bivalent UCHT1 single-chain variable fragments linked to a modified diphtheria toxin (A-dmDT390). VG712 is administered intravenously to selectively deplete CD3-positive T cells. | Mogamulizumab (DRUG): Humanized monoclonal antibody targeting CCR4, administered intravenously for the treatment of T-cell lymphomas, including mycosis fungoides.
- Drugs / treatments
- VG712, Mogamulizumab
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details